Source comparison
Thymosin Alpha-1 60s Age Specific Protocol: Clinical Evidence Comparison
Before starting any thymosin alpha-1 protocol, understanding how dosing strategies perform across age groups helps set realistic expectations for immune restoration timelines and measurable outcomes. 30–50 years 1.6mg 2×/week 22–28% from baseline 25–35% from b
This comparison does not assign a generated winner or score.
- Before starting any thymosin alpha-1 protocol, understanding how dosing strategies perform across age groups helps set realistic expectations for immune restoration timelines and measurable outcomes.
- 30–50 years
- 1.6mg 2×/week
- 22–28% from baseline
- 25–35% from baseline
- eGFR <30 mL/min/1.73m²
- Younger patients achieve peak immune upregulation at lower doses due to preserved thymic output and higher naïve T-cell counts. Receptor saturation occurs faster
- 60–70 years
- 1.6–3.2mg 2×/week
- 12–18% from baseline
- 15–20% from baseline
- eGFR <45 mL/min/1.73m²
- Dose escalation to 3.2mg is warranted only if baseline CD4 <400 or week 4 response is flat. Higher doses don't overcome thymic involution
- 70+ years
- 1.6mg 2×/week (max)
- 8–12% from baseline
- 10–15% from baseline
- eGFR <50 mL/min/1.73m²
- Further dose increases rarely improve outcomes. The limiting factor is thymic stromal cell density, not peptide availability
- Immunosuppressed (any age)
- 3.2mg 2×/week
- Variable (5–15%)
- Variable (8–18%)
- eGFR <60 mL/min/1.73m²
- Concurrent corticosteroid or immunosuppressant use blunts thymosin alpha-1 efficacy by 30–50%. Tapering the immunosuppressant (if medically safe) produces better results than dose escalation